These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29926379)

  • 1. Botulinum Toxin Type A Overdoses: Analysis of the FDA Adverse Event Reporting System Database.
    Kazerooni R; Armstrong EP
    Clin Drug Investig; 2018 Sep; 38(9):867-872. PubMed ID: 29926379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comment on: Botulinum Toxin Type A Overdoses: Analysis of the FDA Adverse Event Reporting System Database.
    Picaut P
    Clin Drug Investig; 2018 Dec; 38(12):1197-1198. PubMed ID: 30390198
    [No Abstract]   [Full Text] [Related]  

  • 3. Response to "Comment on: Botulinum Toxin Type A Overdoses: Analysis of the FDA Adverse Event Reporting System Database".
    Kazerooni R; Armstrong EP
    Clin Drug Investig; 2018 Dec; 38(12):1199-1200. PubMed ID: 30390199
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of benzonatate overdoses among adults and children from 1969-2010 by the United States Food and Drug Administration.
    McLawhorn MW; Goulding MR; Gill RK; Michele TM
    Pharmacotherapy; 2013 Jan; 33(1):38-43. PubMed ID: 23307543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: An analysis of the Food And Drug Administration Adverse Events Reporting System (FAERS).
    Evoy KE; Covvey JR; Peckham AM; Ochs L; Hultgren KE
    Res Social Adm Pharm; 2019 Aug; 15(8):953-958. PubMed ID: 31303196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Insight on the Safety of Erenumab: An Analysis of Spontaneous Reports of Adverse Events Recorded in the US Food and Drug Administration Adverse Event Reporting System Database.
    Sessa M; Andersen M
    BioDrugs; 2021 Mar; 35(2):215-227. PubMed ID: 33609278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
    Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
    Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
    Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse event profiles of ifosfamide-induced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases.
    Shimada K; Hasegawa S; Nakao S; Mukai R; Matsumoto K; Tanaka M; Uranishi H; Masuta M; Nishida S; Shimizu S; Hayashi Y; Suzuki A; Nakamura M
    Cancer Chemother Pharmacol; 2019 Nov; 84(5):1097-1105. PubMed ID: 31502115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
    Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
    Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting Systems.
    Raschi E; Girardi A; Poluzzi E; Forcesi E; Menniti-Ippolito F; Mazzanti G; De Ponti F
    Drug Saf; 2018 Aug; 41(8):745-752. PubMed ID: 29582393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Raschi E; Mazzarella A; Antonazzo IC; Bendinelli N; Forcesi E; Tuccori M; Moretti U; Poluzzi E; De Ponti F
    Target Oncol; 2019 Apr; 14(2):205-221. PubMed ID: 30927173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS).
    Villa-Zapata L; Gómez-Lumbreras A; Horn J; Tan MS; Boyce RD; Malone DC
    Drug Saf; 2022 Aug; 45(8):863-871. PubMed ID: 35834155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of acute kidney injury related to small-molecule protein kinase inhibitors using the FDA adverse event reporting system.
    Fan Q; Ma J; Zhang B; Li Q; Liu F; Zhao B
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):655-662. PubMed ID: 33001273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS).
    Wittayanukorn S; Qian J; Johnson BS; Hansen RA
    J Oncol Pharm Pract; 2017 Mar; 23(2):93-102. PubMed ID: 26661047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
    J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety profile of D-penicillamine: a comprehensive pharmacovigilance analysis by FDA adverse event reporting system.
    Kumar V; Singh AP; Wheeler N; Galindo CL; Kim JJ
    Expert Opin Drug Saf; 2021 Nov; 20(11):1443-1450. PubMed ID: 34259127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
    Raschi E; Poluzzi E; Koci A; Antonazzo IC; Marchesini G; De Ponti F
    Nutr Metab Cardiovasc Dis; 2016 May; 26(5):380-6. PubMed ID: 27067162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases.
    Grosset DG; Tyrrell EG; Grosset KA
    J Rehabil Med; 2015 Feb; 47(2):183-6. PubMed ID: 25325305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.